09.03.2017
B.R.A.I.N. Biotechnology Research And Information Network AG DE0005203947
DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN AG successfully concludes first Annual General Meeting as a stock listed company
DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG /
Key word(s): AGM/EGM
B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN AG
successfully concludes first Annual General Meeting as a stock listed
company
09.03.2017 / 18:41
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
BRAIN AG successfully concludes first Annual General Meeting as a stock
listed company
* New Supervisory Board members with high approval elected
* Change of the auditor as planned
* New Authorized Capital ensures high flexibility for corporate finance
transactions
* Frank Goebel new Chief Financial Officer (CFO)
Zwingenberg, 9 March 2017: B.R.A.I.N. Biotechnology Research and Information
Network AG ("BRAIN AG", ISIN DE0005203947 / WKN 520394) today successfully
held its first Annual General Meeting since the IPO on February 9, 2016. At
the Annual General Meeting 70,77% of the total share capital, the latter
accounting for 16,414,348 shares of BRAIN AG, was represented. All agenda
items, including the new election of four Supervisory Board members, the
election of a new auditor as well as the creation of a new Authorized
Capital, were resolved by a large majority of the participating
shareholders. After the return of Dr Georg Kellinghusen to the Supervisory
Board, Mangement Board member Frank Goebel becomes CFO of BRAIN AG as
previously announced.
Dr Juergen Eck (CEO) particularly focused his speech on last year's IPO and
the business strategy of the BRAIN Group, referring to BRAIN's two segments.
Since the IPO, both segments were expanded further and new milestones have
been achieved. As an example, he mentioned the start of the DOLCE program
for the production of natural sweeteners with its high growth potential.
"Our goal is to pursue the long-term growth path sketched out for the
bioeconomy along with shareholders. We therefore went public at an early
stage of our development. And this strategy so far has been successfull",
explained Dr Juergen Eck.
"The capital market is increasingly willing to contribute to the expansion
of the future sectors around the bioeconomy and to participate in it. This
is also due to the positive perception of the bioeconomy topics in public
discussions."
New auditor elected
Pursuant to the regulations of the EU auditor regulation, BRAIN 2016 carried
out a tender procedure for the determination of an auditor for the financial
year 2016/17. The shareholders approved the proposal of the Supervisory
Board to entrust Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft with
this mandate. The auditor for fiscal year 2015/16, PricewaterhouseCoopers AG
Wirtschaftsprüfungsgesellschaft, was therefore replaced.
Change in the Supervisory Board
At the Annual General Meeting, four of the six Supervisory Board members of
BRAIN AG were to be newly elected. In addition to the re-election of
Professor Dr Klaus-Peter Koller who has already been a member of the
Supervisory Board for many years, Dr Anna Eichhorn, Dr Martin Jager and Dr
Georg Kellinghusen were newly elected to the Supervisory Board. Dr
Kellinghusen had already been a Supervisory Board member before his term in
the Management Board, which started in January 2016.
Creation of a new Authorized Capital
BRAIN AG partially utilised its authorized capital during the IPO in the
fiscal year 2015/16 as planned in an amount of EUR 3.5 million. Against this
background, the Annual General Meeting followed the proposal of the
Management Board and the Supervisory Board to create a new Authorized
Capital in order to enable the company to remain flexible towards potential
corporate finance transactions. Until 8 March 2022, the Management Board may
increase the share capital once or several times by a nominal amount of up
to EUR 8.2 million by issuing just as many new shares.
Frank Goebel becomes Chief Financial Officer
As previously announced at the end of the fiscal year 2015/16, the
appointment of Dr Georg Kellinghusen as a member of the Management Board and
Chief Financial Officer of BRAIN AG ended at the conclusion of the Annual
General Meeting. Dr Kellinghusen played a major role during the successfull
realisation of the BRAIN AG IPO and is now returning to the Supervisory
Board. New CFO is Frank Goebel, who joined the BRAIN Group as managing
director of the company's wholly-owned subsidiary BRAIN Capital GmbH in
February 2015 and had been appointed to the BRAIN Management Board in
November 2016. Dr Juergen Eck (CEO) and Frank Goebel (CFO) now form the
two-man executive board of BRAIN AG.
The detailed voting results and the presentation on agenda item 1 (in German
language) are available for download on the company's website at
www.brain-biotech.de/en/investor-relations/annual-general-meetings.
About BRAIN
BRAIN is one of Europe's leading technology companies in the field of
industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN
identifies previously untapped, efficient enzymes, microbial producer
organisms or natural substances from complex biological systems that can be
put to industrial use. The innovative solutions and products developed by
help of this "Toolbox of Nature" are successfully applied in the chemistry,
the cosmetics and the food industries. Today, BRAIN's business model is
based on two pillars -"BioScience" and "BioIndustrial". The first pillar,
"BioScience", comprises its - frequently exclusive -collaboration business
with industrial partners. The second pillar "BioIndustrial" comprises the
development and commercialisation of BRAIN's own products and active product
components. Further information is available at www.brainbiotech.de/en.
Contact:
B.R.A.I.N
Biotechnology Research And Information Network AG
Dr. Martin Langer
Executive Vice President
Corporate Development
Darmstädter Str. 34-36
64673 Zwingenberg, Germany
Tel.: +49-6251-9331-16
Fax: +49-6251-9331-11
E-Mail: [email protected]
www.brain-biotech.de
Disclaimer
This press release contains forward- looking statements. These statements
reflect the current views, expectations, and assumptions of the management
of BRAIN AG and are based on information currently available to the
management. Forward-looking statements are not guarantees of future
performance and involve known and unknown risks and uncertainties that could
cause actual results, performance or events to differ materially from those
expressed or implied in such statements. There are numerous factors which
could influence the future performance by and future developments at BRAINAG
and the BRAIN Group. Such factors include, but are not limited to, changes
in the general economic and competitive environment, risks associated with
capital markets, currency exchange rate fluctuations, changes in
international and national laws and regulations, in particular with respect
to tax laws and regulations, and other factors. BRAIN AGdoes not undertake
any obligation to update or revise any forward-looking statements.
---------------------------------------------------------------------------
09.03.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: B.R.A.I.N. Biotechnology Research And Information Network
AG
Darmstädter Straße 34-36
64673 Zwingenberg
Germany
Phone: +49 (0) 62 51 / 9331-0
Fax: +49 (0) 62 51 / 9331-11
E-mail: [email protected]
Internet: www.brain-biotech.de
ISIN: DE0005203947
WKN: 520394
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Munich,
Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
552691 09.03.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
B.R.A.I.N. Biotechnology Research And Information Network AG ISIN: DE0005203947 können Sie bei EQS abrufen
Biotechnologie , 520394 , BNN , XETR:BNN